BioXcel Therapeutics, Inc. (BTAI)

Market Cap	33.91M
Revenue (ttm)	868,000
Net Income (ttm)	-50.95M
Shares Out	6.06M
EPS (ttm)	-11.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,245,296
Open	7.29
Previous Close	6.80
Day's Range	5.16 - 7.36
52-Week Range	1.17 - 13.36
Beta	0.06
Analysts	Strong Buy
Price Target	39.50 (+605.36%)
Earnings Date	Aug 12, 2025

About BTAI

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 8, 2018
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: BTAI
• Website: https://www.bioxceltherapeutics.com

Financial Performance

In 2024, BioXcel Therapeutics's revenue was $2.27 million, an increase of 64.20% compared to the previous year's $1.38 million. Losses were -$59.60 million, -66.71% less than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for BTAI stock is "Strong Buy." The 12-month stock price target is $39.5, which is an increase of 605.36% from the latest price.

Price Target

$39.5

(605.36% upside)

Analyst Consensus: Strong Buy